← Back to Screener
MediWound Ltd. (MDWD)
Price$13.82
Value ScoreD
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-30.94%
Price vs S&P 500 (4W)-18.80%
VGM Score27.21
Market Capitalization$182.06M
All Metrics
Book Value / Share (Quarterly)$3.22
P/TBV (Annual)5.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-13.82%
Cash Flow / Share (Quarterly)$-1.96
Price vs S&P 500 (YTD)-33.31%
Gross Margin (TTM)19.61%
Net Profit Margin (TTM)-180.30%
EPS (TTM)$-2.26
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-2.26
Revenue Growth (5Y)-4.86%
EPS (Annual)$-2.10
ROI (Annual)-45.56%
Gross Margin (Annual)19.19%
Net Profit Margin (5Y Avg)-91.44%
Cash / Share (Quarterly)$3.47
Revenue Growth QoQ (YoY)-62.71%
ROA (Last FY)-27.68%
Revenue Growth TTM (YoY)-24.64%
EBITD / Share (TTM)$-2.20
ROE (5Y Avg)-95.84%
Operating Margin (TTM)-193.53%
Cash Flow / Share (Annual)$-1.68
P/B Ratio4.40x
P/B Ratio (Quarterly)5.00x
Net Income / Employee (Annual)$-197,300
EV / Revenue (TTM)10.05x
Net Interest Coverage (TTM)-12.46x
ROA (TTM)-31.87%
EV / EBITDA (TTM)20.73x
EPS Incl Extra (Annual)$-2.10
Current Ratio (Annual)2.33x
Quick Ratio (Quarterly)2.19x
3-Month Avg Trading Volume0.09M
52-Week Price Return-32.85%
Revenue / Employee (TTM)$119,700
Tangible BV / Share (Quarterly)$3.22
P/S Ratio (Annual)10.74x
Asset Turnover (Annual)0.20x
52-Week High$22.50
Operating Margin (5Y Avg)-81.10%
EPS Excl Extra (Annual)$-2.10
CapEx CAGR (5Y)43.02%
Tangible BV CAGR (5Y)24.22%
26-Week Price Return-15.01%
Quick Ratio (Annual)2.16x
13-Week Price Return-18.21%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)2.41x
Enterprise Value$145.54M
Revenue / Share Growth (5Y)-23.24%
Asset Turnover (TTM)0.18x
Book Value / Share Growth (5Y)-2.71%
Revenue / Employee (Annual)$140,200
Inventory Turnover (Annual)4.04x
Pretax Margin (Annual)-139.81%
Cash / Share (Annual)$4.14
3-Month Return Std Dev45.86%
Gross Margin (5Y Avg)27.60%
Net Income / Employee (TTM)$-215,700
ROE (Last FY)-54.73%
Net Interest Coverage (Annual)-0.83x
EPS Basic Excl Extra (Annual)$-2.10
Receivables Turnover (TTM)3.65x
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-2.26
Receivables Turnover (Annual)5.28x
ROI (TTM)-55.56%
P/S Ratio (TTM)12.57x
Pretax Margin (5Y Avg)-90.90%
Revenue / Share (Annual)$1.49
Tangible BV / Share (Annual)$3.40
Price vs S&P 500 (52W)-61.06%
Year-to-Date Return-22.37%
5-Day Price Return-13.57%
EPS Normalized (Annual)$-2.10
ROA (5Y Avg)-37.35%
Net Profit Margin (Annual)-140.80%
Month-to-Date Return-13.15%
Cash Flow / Share (TTM)$-1.35
EBITD / Share (Annual)$-2.12
Operating Margin (Annual)-148.98%
LT Debt / Equity (Annual)7.75x
ROI (5Y Avg)-79.59%
LT Debt / Equity (Quarterly)17.96x
EPS Basic Excl Extra (TTM)$-2.26
P/TBV (Quarterly)5.00x
P/B Ratio (Annual)5.42x
Inventory Turnover (TTM)2.79x
Pretax Margin (TTM)-179.28%
Book Value / Share (Annual)$3.40
Price vs S&P 500 (13W)-27.95%
Beta0.13x
P/FCF (Annual)24.28x
Revenue / Share (TTM)$1.12
ROE (TTM)-67.22%
52-Week Low$14.14
vGradeD
gGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.23est. -0.67
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDWDMediWound Ltd. | D | F | D | $13.82 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $24.06 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.82 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $5.49 |
| CGCCanopy Growth Corporation Common Shares | B | D | D | $1.08 |
| USNAUSANA Health Sciences Inc | B | D | D | $18.33 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.61 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.46 |
| ACBAurora Cannabis Inc. Common Shares | B | D | D | $3.64 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.91 |
| BTMDBiote Corp. Class A Common Stock | A | D | D | $2.11 |
About
MediWound Ltd is a biopharmaceutical company developing treatments for severe burns and hard-to-heal wounds. Its lead product, NexoBrid, is FDA-approved for eschar removal in severe burns and offers a non-surgical alternative to conventional debridement. The company is advancing a pipeline including EscharEx for chronic wound debridement and MW005 for non-melanoma skin cancer, with revenue primarily generated in the United States.